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Vitamin D status in an urban Spanish HIV-infected patient cohort
and its relationship with most frequent antiretroviral therapy
regimens
Cervero, M; Agud, J; Torres, R and Jusdado, J
H. Severo Ochoa, Internal Medicine/Infectious Diseases, Legane ´s, Spain.
Purpose
We assessed vitamin D status in HIV-infected patients and its relation to classic, related-HIV risk factors and therapeutic
regimens.
Methods
Out of 450 HIV-infected patients followed in the H. Severo Ochoa (Madrid, Spain), we selected 352 patients in which vitamin D
levels had been assessed (2009 to 2010). We describe demographics, cART duration, cART, viral load (VL), CD4 cell count,
25(OH)D levels, iPTH, MDRD, serum albumin and calcium. Vitamin D status cutoff points were: 1. deficiency (vitDd): 25(OH)D
levels B20 ng/mL; 2. insuficiency (vitDi): 20 to 29.99 ng/mL and 3. optimal (vitDo): 25(OH)D ] 30 ng/mL.
Results
Median CD4 cell count was 501 cells/mL; median VL 40 copies/mL. 277 patients (78.7%) had less than 50 copies/mL. 310
patients (88.1%) were on cART.The proportions of patients with vitDd, vitDi and vitDo were 155/352 (44%), 97 (27.6%) and 100
(28.5%). Black patients had 14.2% of vitDd (22 patients out of 155 patients with vitDd), 7.2% (7/97) vitDi and 1% (1/100) vitDo
(p.001) vs. global sample; therefore, 29 out of 30 (96.7%) black patients had vitDd/vitDi, vs. 71.6% in global sample. Former
IDUs had more vidDo (pB0.001 vs. other risk groups). Among patients with less than 50 copies/mL, the proportions of vitDd,
vitDi and vitDo were 77.4%, 68% and 91% respectively, (p.0001). Of the cART, only PI monotherapy was associated with
significant differences in vitD (see Table).
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vitDd n155 (44%) vitDi n97 (27.6%) vitDo n100 (28.4%) p
Age 28 (2334) 28 (2535) 27 (2335) 0.77
Gender n (%) Female/male 59 (38.1%) 96 (61.6%) 23 (23.7%) 74 (76.39%) 34 (34%) 66 (66%) 0.06
Ethnic background n (%)
Caucasian/Black/Hispanic
125 (80.6%) 22 (14.2%)
8 (5.2%)
83 (85.6%) 7 (7.2%)
7 (7.2%)
91 (91%) 1 (1%)
8 (8%)
0.07 0.001* 0.64
Risk factor HTX/MSM/IDU/other 76 (49.1%) 18 (11.6%)
59 (38.1%) 2 (1.3%)
34 (35.1%) 27 (27.8%)
33 (34%) 3 (3.1%)
27 (27%) 9 (9%)
63 (63%) 1 (1%)
0.001* 0.0001*
0.0001* 0.45
Calcium (mg/dL) 9.3 (99.6) 9.2 (8.59.5) 9.2 (8.99.5) 0.08
Albumin (g/dL) 4.4 (4.24.6) 4.4 (4.14.6) 4.4 (4.24.6) 0.59
iPTH (pg/mL) 48.2 (34.267.8) 46 (32.859.45) 45.2 (34.5759.9) 0.51
Phosphorus (mg/dL) 3.29 (3.13.6) 3.296 (2.93.3) 3.296 (33.296) 0.053
Glomerular filtration rate (MDRD) 88.2 (77.3102) 85.9 (74.795.5) 84 (73.992.3) 0.03
GFR B60 n (%) 6 (3.9%) 1 (1%) 9 (9%) 0.02
Blood glucose (mg/dL) 96 (88104) 96 (89104) 97 (89104) 0.99
HCV (%) 92 (59.4%) 58 (59.8%) 33 (33%) 0.0001*
HBV (%) 3 (1.9%) 6 (6.2%) 4 (4%) 0.22
CD4 519 (334700) 449 (307637) 505 (360660) 0.36
HIV copies/mL (%) 50B50 35 (22.6%) 120 (77.4%) 31 (32.4%) 66 (68%) 9 (9%) 91 (91%) 0.0001*
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1On multivariate analysis following variables were related to increased risk of vitD insuficiency/deficiency, black vs. white race
(OR 10.6 [95% CI 1.294], p.033); heterosexual/MSM risk vsm IDU risk groups (OR 2.37 [95% CI 1.134.93], p.022) and
(OR 3.25 [95% CI 1.258.50], p.016) and VL 50 copies/mL (OR 2.56 [95% CI 1.107.25], p.040). Less risk of vitamin D
insufficiency/deficiency was found in patients on PI monotherapy vs. no treatment (OR 0.08 [95% CI 0.010.6], p.018);
Hispanic (South American) patients vs. white (OR 0.18 [95% CI 0.050.68], p.012) and summer/autumn vs. spring samples (OR
0.015 [95% CI 0.0020.116], p.0001 summer) and (OR 0.013 [95% CI 0.020.099), p.0001, for autumn).
Conclusions
1: Vitamin D status was associated with ethnic background, season and non-suppressed VL. 2: Former IDUs had less vitamin D
deficiency/insufficiency, perhaps due to more outdoor jobs. 3: As in the MONET study, PI monotherapy had a positive impact
on vitD.
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HAART, n (%) 73 (47.1%) 45 (46.4%) 67 (67%) 0.003*
Season, n (%) spring/summer/
autumn/winter
52 (33.5%) 20 (12.9%)
35 (22.6%) 48 (31%)
15 (15%) 25 (25.8%)
38 (39.2%) 19 (19.6%)
1 (1%) 37 (37%)
58 (58%) 4 (4%)
0.0001* 0.0001*
0.0001* 0.0001*
HAART regimens (patients with
B50 copies)
vitDd n 118 VitDi n64 VitDo n91
Duration (months) 85 (40143) 64 (28138) 86 (43140) 0.344
NNRTITDF 36 (30.51%) 23 (35.94%) 21 (23.07%) 0.258
NNRTIno_TDF 16 (13.56%) 8 (12.5%) 9 (9.89%) 0.745
PITDF 28 (23.73%) 15 (23.44%) 25 (27.47%) 0.728
PInoTDF 14 (11.28%) 9 (14.06%) 15 (16.48%) 0.602
NNRTIPITDF 1 (0.85%) 0 (0%) 0 (0%) 0.519
NNRTIPInoTDF 3 (3%) 1 (1.56%) 3 (3.29%) 0.781
OtherTDF 2 (2.54%) 1 (1.56%) 0 (0%) 0.475
Otherno TDF 9 (7.63%) 5 (7.81%) 5 (5.49%) 0.821
PI monotherapy 9 (7.63%) 2 (3.12%) 13 (14.28%) 0.039*
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